AQP11 Antibody

What is the basic structure of AQP11 and how does it differ from other aquaporins?

AQP11 belongs to the aquaporin family but has unusual structural features that distinguish it from conventional aquaporins. Unlike most aquaporins with conserved NPA (asparagine-proline-alanine) motifs, AQP11 contains an NPC motif that is essential for its full functional expression . The protein presents a conserved structure of six transmembrane domains with intracellular N- and C-termini . Functionally, AQP11 forms a tetramer, with each subunit containing a separate pore, creating a channel unit with four pores .

Chemical cross-linking and co-immunoprecipitation experiments using DSP and paraformaldehyde have confirmed that AQP11 forms oligomeric structures, similar to other aquaporins like AQP4 . This tetrameric arrangement is critical for its function in transporting water, glycerol, and notably, hydrogen peroxide across cellular membranes .

What are the most critical considerations when selecting an AQP11 antibody for brain tissue research?

When selecting an AQP11 antibody for brain tissue research, several critical factors must be considered:

• Antibody specificity: Validate using AQP11-deficient mice or knockdown cell lines to ensure specificity. Research has shown that raising antibodies against AQP11 is difficult, and some commercially available antibodies lack sufficient specificity .

• Target epitope location: Consider whether the antibody targets intracellular or extracellular domains. Antibodies targeting the C-terminus, N-terminus, or extracellular loops may yield different staining patterns . For instance, antibodies against amino acid residues 140-151 of rat AQP11 (2nd extracellular loop) have proven effective for Western blot analysis of brain lysates .

• Cross-reactivity: Ensure minimal cross-reactivity with other aquaporins, particularly AQP0, which is also expressed in brain tissue and upregulated alongside AQP11 in response to stressors .

• Validated applications: Confirm the antibody has been validated for your specific application (Western blot, immunohistochemistry, immunocytochemistry, etc.) in brain tissue .

• Species reactivity: Verify compatibility with your experimental model, as differences exist between human, rat, and mouse AQP11 .

How should AQP11 antibody validation be performed prior to experimental use?

A comprehensive validation protocol for AQP11 antibodies should include:

• Negative controls:

  • Test with AQP11-deficient tissue/cells from knockout models

  • Preincubation with the antigenic peptide should abolish signal

  • Include isotype controls to assess non-specific binding

• Positive controls:

  • Test in tissues known to express high levels of AQP11 (kidney, liver, brain)

  • Use cells transfected with AQP11 expression vectors

• Western blot validation:

  • Confirm appropriate molecular weight bands (32 kDa in brain, kidney, heart, and skeletal muscle; 25 kDa in testes, kidney, and liver)

  • Perform deglycosylation (PNGase) and dephosphorylation (lambda protein phosphatase) treatments to identify potential post-translational modifications

• Immunocytochemistry validation:

  • Co-staining with subcellular markers (Na⁺-K⁺-ATPase for plasma membrane, ER CytoPainter for endoplasmic reticulum)

  • Confocal microscopy with Z-stack analysis to confirm subcellular localization

• siRNA knockdown verification:

  • Perform siRNA knockdown experiments to confirm antibody specificity

  • Multiple siRNA constructs should be tested to rule out off-target effects

How can researchers effectively study AQP11 expression changes in response to stressors?

To investigate AQP11 expression changes in response to stressors, researchers should consider the following experimental design approach:

• Cell culture models:

  • For brain research, use established cell lines like 1321N1 (astroglia) and SHSY5Y (neurons, differentiated with retinoic acid)

  • Transfect cells with AQP11 constructs (tagged with GFP, Myc, or V5) for localization studies

• Stressor application protocols:

  • Inflammatory stress: Apply lipopolysaccharide (LPS) at 10-100 ng/ml for 24 hours

  • Hypoxic stress: Expose cells to N₂ for 5 minutes, followed by 0-24 hours of normoxia

• Expression analysis methods:

  • Transcript level: Monitor changes using RT-PCR with primers spanning different exons to suppress genomic DNA amplification

  • Protein level: Quantify using immunocytochemistry with appropriate markers for subcellular localization

  • Functional assessment: Measure peroxiporin activity using melondialdehyde (MDA) assays to quantify lipid peroxidation after H₂O₂ exposure

• Controls and normalization:

  • Include non-stressed controls for baseline expression

  • Use GAPDH as an internal control for RT-PCR normalization

  • Employ scrambled siRNA controls for knockdown experiments

What methods are most effective for visualizing AQP11 subcellular localization?

For optimal visualization of AQP11 subcellular localization, a multi-modal approach is recommended:

• Sample preparation:

  • Fix cells with 1:1 acetone and methanol for 15 minutes at room temperature

  • Block with 0.1% TWEEN with 1% bovine serum albumin (BSA) for 1 hour

• Co-localization markers:

  • Plasma membrane: Co-stain with Na⁺-K⁺-ATPase (e.g., mouse anti-human antibody, 1:100)

  • Endoplasmic reticulum: Use ER CytoPainter (1:1000) prepared in 1× buffer solution

  • Nuclear staining: Apply Hoechst nuclear stain (1:1500)

• Imaging techniques:

  • Confocal microscopy with Z-stack acquisition at 60X magnification

  • IMARIS software for 3D reconstruction and co-localization analysis

  • HALO Area-Quantification FL program for signal intensity measurement

• Biotinylation assays:

  • For cell surface expression quantification, perform biotinylation experiments to distinguish between intracellular and plasma membrane populations

How can researchers investigate AQP11's role as a peroxiporin in neuroprotection?

AQP11's emerging role as a peroxiporin (H₂O₂-transporting channel) in neuroprotection can be investigated through:

• Peroxiporin activity assessment:

  • Measure hydrogen peroxide transport using fluorescent H₂O₂ probes

  • Quantify lipid peroxidation via melondialdehyde (MDA) assays after H₂O₂ exposure

  • Compare responses between control cells and those with upregulated or knocked-down AQP11

• Modulation of AQP11 expression:

  • Upregulation: Pre-treat cells with LPS (100 ng/ml for 24 hours) to boost peroxiporin expression

  • Downregulation: Use siRNA knockdown with validated sequences (optimize for 72-hour incubation)

  • Mutation studies: Introduce point mutations in the NPC motif to assess functional impact

• Oxidative stress response experiments:

  • Measure ROS levels after various stressors with and without AQP11 modulation

  • Assess changes in antioxidant enzyme activities

  • Evaluate cell viability and recovery after oxidative challenge

• Neuroprotection models:

  • In vitro: Compare H₂O₂-induced damage in cells with different AQP11 expression levels

  • Ex vivo: Use brain slice cultures from wild-type and AQP11-modified animals

  • In vivo: Assess AQP11's role in animal models of neurodegeneration or ischemia

Research has shown that pretreatment with LPS to boost peroxiporin expression lowers subsequent H₂O₂-induced MDA responses by approximately 50% compared to controls, while siRNA knockdown of AQP0 increases lipid peroxidation by about 17% after H₂O₂ exposure, with a similar trend observed for AQP11 siRNA .

How do AQP11 expression patterns change in neurodegenerative conditions like Alzheimer's disease?

Transcriptomic analyses have identified correlations between AQP11 expression and Alzheimer's disease (AD) status . To further investigate these patterns:

• Human tissue analysis:

  • Compare AQP11 mRNA and protein levels in post-mortem brain samples from AD patients and age-matched controls

  • Assess regional differences across cortex and hippocampus, focusing on areas with known pathology

  • Correlate expression with markers of disease progression (amyloid plaques, tau tangles)

• Cell-type specific changes:

  • Use double-labeling techniques to identify which neural cell types (neurons vs. glia) show altered AQP11 expression

  • Consider differential responses between cell types, as glial cells (1321N1) showed robust peroxiporin upregulation after stress, while neuronal cells (SHSY5Y) exhibited more subtle effects

• Temporal dynamics:

  • Investigate whether AQP11 changes precede or follow neurodegeneration

  • Consider slower protein translation in neurons that might delay protective effects of AQP11

• Functional consequences:

  • Assess whether AD-related AQP11 changes affect peroxiporin activity and cellular protection

  • Investigate potential interactions with other AD-related pathways

What are the most common issues with AQP11 immunodetection and how can they be resolved?

Several challenges are frequently encountered when working with AQP11 antibodies:

• Low signal intensity:

  • Cause: Insufficient AQP11 expression or antibody sensitivity

  • Solution: Consider upregulating AQP11 expression with LPS (100 ng/ml, 24 hours) before detection

  • Alternative: Try antibodies targeting different epitopes; antibodies against the C-terminus may yield different results than those against the N-terminus or extracellular loops

• Non-specific binding:

  • Cause: Cross-reactivity with other aquaporins or proteins

  • Solution: Always include negative controls (AQP11-deficient samples or peptide competition assays)

  • Alternative: Pre-adsorb antibody with the antigenic peptide to confirm specificity

• Inconsistent band patterns in Western blots:

  • Cause: Tissue-specific expression patterns or post-translational modifications

  • Solution: Be aware that AQP11 typically appears as a 32 kDa band in brain, heart, and skeletal muscle, but as a 25 kDa band in testes, kidney, and liver

  • Verification: Perform deglycosylation and dephosphorylation assays to identify modifications

• Poor membrane localization:

  • Cause: AQP11 is predominantly localized in the endoplasmic reticulum, with lesser amounts in the plasma membrane

  • Solution: Use subcellular fractionation techniques to separate membrane fractions

  • Alternative: Perform biotinylation assays to specifically label and quantify cell surface proteins

How can contradictory results between transcript and protein levels of AQP11 be reconciled?

Discrepancies between AQP11 transcript and protein levels are not uncommon, as observed in SHSY5Y neurons that showed increased AQP11 transcript but minimal protein change after LPS treatment . To address such inconsistencies:

• Consider temporal dynamics:

  • Protein synthesis may require longer than the standard 24-hour experimental window, especially in neuronal cells

  • Design time-course experiments extending beyond 24 hours to capture delayed translation

• Assess post-transcriptional regulation:

  • Investigate microRNA regulation of AQP11 translation

  • Examine protein degradation rates using proteasome inhibitors

• Evaluate cell-type specific differences:

  • Compare translation efficiency between different cell types (e.g., 1321N1 vs. SHSY5Y)

  • Consider intrinsic differences in protein synthesis machinery

• Technical validation:

  • Confirm antibody specificity using multiple antibody clones

  • Employ orthogonal methods (mass spectrometry, in situ hybridization) to validate findings

  • Use tagged AQP11 constructs (GFP, Myc, V5) to track expression independent of antibody detection

By carefully considering these methodological aspects, researchers can better reconcile discrepancies and develop more accurate models of AQP11 regulation in different cellular contexts.